Stiripentol Suppliers & Bulk Manufacturers
Available Forms: Capsules / Oral Suspension
Available Strengths: 250 mg, 500 mg
Reference Brands: Diacomit (UES/EU)
Category:
Neurology
Stiripentol is available in Capsules / Oral Suspension
and strengths such as 250 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Stiripentol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Stiripentol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Stiripentol is an anticonvulsant medication used for the treatment of Dravet syndrome, a rare and severe genetic epilepsy that begins in infancy and is characterized by refractory seizures. Marketed under the brand name Diacomit, stiripentol is approved in the European Union as an adjunctive therapy in combination with clobazam and valproate for patients whose generalized tonic-clonic seizures are not adequately controlled with standard treatment.
Stiripentol exerts its antiepileptic effects by enhancing gamma-aminobutyric acid (GABA)–mediated neurotransmission in the central nervous system, helping to reduce neuronal excitability. In addition, it inhibits specific cytochrome P450 enzymes, increasing the plasma concentrations and therapeutic effectiveness of co-administered antiepileptic drugs such as clobazam. This synergistic action contributes to improved seizure control in patients with severe myoclonic epilepsy in infancy.
The medication is administered orally in capsule form or as a powder for oral suspension and is prescribed under specialist supervision due to its potential for drug–drug interactions. Stiripentol plays a critical role in the long-term management of Dravet syndrome, helping reduce seizure frequency and severity in affected patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing